SCHEMBL24569747

SCHEMBL24569747

Cc1c(Oc2ccc3c(c2)ncn3C)ccc([N+](=O)[O-])c1F

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 2/20 0.43
ERBB2 P04626 1/20 0.42
ALDH1A1 P00352 6/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PKM P14618 1/20 0.39
MAPT P10636 8/20 0.38
HTT P42858 4/20 0.38
LMNA P02545 3/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
HSPB1 P04792 1/20 0.38
TDP1 Q9NUW8 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
TTR P02766 1/20 0.35
PPOX P50336 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050278 0.89 KMT2A (0.40) KMT2AGAAHPGDERBB2ALDH1A1
SCHEMBL30050113 0.88 KMT2A (0.42) KMT2AGAAHPGDERBB2ALDH1A1
SCHEMBL29309626 0.85 KMT2A (0.42) KMT2AGAAHPGDALDH1A1SMN1; SMN2
SCHEMBL30050403 0.84 GRM5 (0.41) GAAALDH1A1SMN1; SMN2PKMMAPT
SCHEMBL24569525 0.84 KMT2A (0.44) KMT2AGAAHPGDALDH1A1SMN1; SMN2
SCHEMBL24570292 0.83 KMT2A (0.42) KMT2AGAAHPGDERBB2ALDH1A1
SCHEMBL30049938 0.83 ALDH1A1 (0.36) GAAALDH1A1SMN1; SMN2PKMMAPT
SCHEMBL30050051 0.83 KMT2A (0.42) KMT2AGAAHPGDALDH1A1SMN1; SMN2
SCHEMBL24569478 0.81 KMT2A (0.44) KMT2AGAAHPGDERBB2ALDH1A1
SCHEMBL29887844 0.81 KMT2A (0.44) KMT2AGAAHPGDERBB2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025202889-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2025-10-02 WO disclosed
CN-118459485-A Amino-substituted heterocycles for the treatment of cancers with EGFR mutations 纽威伦特公司 2024-08-09 CN disclosed
EP-4323356-A1 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS Nuvalent, Inc. (US) 2024-02-21 EP disclosed
WO-2022221227-A9 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS NUVALENT, INC. (US) 2023-11-30 WO disclosed
EP-4267137-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 Enliven Inc. (US) 2023-11-01 EP disclosed
WO-2022269531-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2022-12-29 WO disclosed
WO-2022221227-A1 AMINO-SUBSTITUTED HETEROCYCLES FOR TREATING CANCERS WITH EGFR MUTATIONS NUVALENT, INC. (US) 2022-10-20 WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed
WO-2022140769-A1 LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 ENLIVEN THERAPEUTICS, INC. (US) 2022-06-30 WO disclosed